PMak

Visit AngioDynamics Cardiovascular at booth #423, at SCAI 2026 for hands-on experiences with the AlphaVac System and the AngioVac System and learn how we are revolutionizing thrombectomy treatment. Risk Info: angiodynamics.com/about-us/risk-… #PE #AlphaVac #Thrombectomy

@BillyQMMA Let’s go!

Happy first playoff game in 15 long years Buffalo Sabres fans 💪🏼💪🏼💪🏼💪🏼

Join team #Angio at our upcoming Satellite Session at #SCAI2026 Thursday, 4/23, 6:00-7:30 PM. Located at 510a, level 5. Risk Info: bit.ly/4mg2mI9 #AngioDynamics #PE #AlphaVac #Thrombectomy #CardiovascularCare

CVSF 3 brought energy, ideas, and innovation together in Fort Lauderdale – and now, we’re officially 6 months out from CVSF 4 in Boston! The countdown is on to Boston! Click below to #SubmitYourInterest! bit.ly/4tpTAva GL/NA/SM/4338 Rev 01 04/2026

The APEX-Return Study is a major clinical initiative from AngioDynamics CV, focused on advancing care for patients with acute PE. Led by PI's Dr. Sukhdeep Basra, and Dr. Peter Monteleone. Contact: medicalaffairs@angiodynamics.com Risk info: bit.ly/3V7wxGc

Buffalo vs Everybody ⚔️

This March, AngioDynamics CV would like to recognize the importance of blood clot awareness month, #BCAM2026. We are proud to partner with the National Blood Clot Alliance. Learn more about our cardiovascular portfolio at: bit.ly/4aBc7P9

Navigate with confidence using the AlphaVac F18-85 System, purpose-built to deliver control, precision, and safety during #PE interventions. Learn more: bit.ly/4aBc7P9 Risk info: bit.ly/3V7wxGc Dr. Serhal is a paid consultant of AngioDynamics.

We would like to thank Dr. Patrick Muck and Dr. Sripal Bagalore for delivering an inspiring keynote address at the 2026 CVSF 🫀 Learn more: bit.ly/4aBc7P9 All physicians mentioned are paid consultants of AngioDynamics. US/NA/SM/4144 Rev. 01 02/2026

“Pulmonary embolism continues to be a leading cause of morbidity and mortality across Europe, underscoring the need for treatment strategies that are both safe and effective.” Erik Klok, MD ▶️ bit.ly/4nvNdE1 #RECOVER-AV #AlphaVac #PE Risk: bit.ly/3UFe4Rf

The #AlphaVac System is an efficient way to remove clot from large vessels utilizing the proprietary funnel cannula technology, ergonomic reloadable handle, and transparent waste bag to achieve removal of clot with control. ▶️ bit.ly/4nvNdE1 #RECOVER-AV

CVSF topics address the underlying need for devices, highlight the importance of industry collaboration, and promote peer-driven learning to advance innovation. bit.ly/4aBc7P9 bit.ly/3V7wxGc #CVSF2026 #JoinUs #AngioDynamicsCardiovascular #CardiovascularCare

The #RECOVER-AV trial is to support the adoption of the #AlphaVac F18-85 System in the global market by demonstrating its safety and efficacy in treating confirmed acute, intermediate-risk PE and providing long-term functional outcomes for patients. ▶️ bit.ly/4nvNdE1

Join us at CVSF, convening leading experts, thought leaders, innovators in cardiology, clinical research, and medical innovation to explore the latest technologies shaping the future of CV care. bit.ly/4aBc7P9 bit.ly/3V7wxGc #CVSF2026 #CardiovascularCare

Enhanced Navigation. Unmatched Control. Procedural Efficiency. AngioDynamics is revolutionizing PE treatment with the #AlphaVac F18-85 System by optimizing navigation between the pulmonary vasculature. ▶️ bit.ly/4nvNdE1 #RECOVER-AV #PE Risk: bit.ly/3UFe4Rf

The #RECOVER-AV trial is to support the adoption of the #AlphaVac F18-85 System in the global market by demonstrating its safety and efficacy in treating confirmed acute, intermediate-risk #PE and providing long-term functional outcomes for patients. ▶️ bit.ly/4nvNdE1

Your Expertise. Your Impact. Will we see you at #CVSF3? Learn more: bit.ly/4aBc7P9 #YourExpertiseYourImpact #CardiovascularCare #AlwaysListening GL/NA/SM/4073

Are you ready to share your bold ideas, cutting-edge research, and clinical innovation in #CardiovascularCare? The Young Investigators Pitch at #CVSF3 is your chance to make a high-impact impression! Deadline: January 25, 2026 Submit Here: bit.ly/FellowsCVSF2026

“Performing the first case in the #RECOVER-AV study marks an important step forward in expanding treatment options for patients with intermediate-risk #pulmonaryembolism.” Aleksander Araszkiewicz, MD, PhD, Assistant Professor  ▶️ bit.ly/4nvNdE1 bit.ly/3UFe4Rf

Wishing you a holiday season filled with warmth, joy, and good health. We look forward to a bright and prosperous new year together.  Happy Holidays!